Kyowa Kirin Co., Ltd.

Riken Corporation

Kyowa Hakko Kirin Co., Limited

Akifumi Kato

Shigeyuki Yokoyama

Yasuhisa Shiraishi

Kensaku Sakamoto

Akiko Matsumoto

Tatsuo Yanagisawa

Kaname Kimura

Masakazu Homma

Yoshimi Yamaguchi

Kazumasa Ohtake

Hiroshi Sato

Yutaka Kanda

Mitsuo Satoh

Tsuyoshi Yamada

Ryosuke Nakano

Toshimasa Harumoto

Harue Nishiya

An object of the present invention is to provide a bispecific antibody having an agonist activity to a GM-CSF receptor, and a bispecific antibody fragment thereof. The present invention relates to a bispecific antibody or a bispecific antibody fragment thereof containing: a first antigen-binding domain; and a second antigen-binding domain, in which one of the first antigen-binding domain and the second antigen-binding domain is an antigen-binding domain binding to CD116, and the other one is an antigen-binding domain binding to CD131.

Bispecific antibody that binds to CD116 and CD131

The present invention relates to a monoclonal antibody or antibody fragment thereof as a human IgG antibody including at least one lysine derivative in a constant region of the human IgG antibody; a modified antibody or antibody fragment thereof, wherein the lysine derivative is modified; a nucleic acid including a nucleotide sequence encoding the antibody or antibody fragment thereof; a vector including the nucleic acid; a transformed cell obtained by introducing the vector into a host cell; a method for producing the antibody or antibody fragment thereof; and a composition containing the antibody or antibody fragment thereof.

Antibody with non-natural amino acid introduced therein

A pharmaceutical agent for treating a disease such as inflammatory diseases, blood coagulation diseases associated with deficiency of Protein S has been required. The present invention provides a Protein S composition comprising recombinant Protein S molecules having complex type N-glycoside-linked sugar chains, wherein the Protein S has a higher binding activity to a receptor for advanced glycation end products (hereinafter referred to as 'RAGE') than native Protein S present in healthy human blood, and also has a higher ratio of sugar chains in which fucose is not bound to the complex type N-glycoside-linked sugar chains bound to Protein S than native Protein S present in healthy human blood.

Recombinant protein S composition

Growing community of inventors

Tokyo, Japan

Akifumi Kato